Last reviewed · How we verify
NUFYMCO (RANIBIZUMAB-LEYK)
NUFYMCO (generic name: RANIBIZUMAB-LEYK) is a drug developed by FORMYCON AG. It is currently FDA-approved.
NUFYMCO is a vascular endothelial growth factor A inhibitor, classified as an antibody drug. It targets vascular endothelial growth factor A, long form, and is also known by various synonyms including BYOOVIZ, CIMERLI, and FYB-201.
At a glance
| Generic name | RANIBIZUMAB-LEYK |
|---|---|
| Sponsor | FORMYCON AG |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NUFYMCO CI brief — competitive landscape report
- NUFYMCO updates RSS · CI watch RSS
- FORMYCON AG portfolio CI
Frequently asked questions about NUFYMCO
What is NUFYMCO?
NUFYMCO (RANIBIZUMAB-LEYK) is a pharmaceutical drug developed by FORMYCON AG.
Who makes NUFYMCO?
NUFYMCO is developed and marketed by FORMYCON AG (see full FORMYCON AG pipeline at /company/formycon-ag).
What is the generic name of NUFYMCO?
RANIBIZUMAB-LEYK is the generic (nonproprietary) name of NUFYMCO.
What development phase is NUFYMCO in?
NUFYMCO is FDA-approved (marketed).
Related
- Manufacturer: FORMYCON AG — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing